Zacks: Analysts Expect Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Will Announce Earnings of -$0.08 Per Share

Equities analysts predict that Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating) will report earnings per share of ($0.08) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Citius Pharmaceuticals’ earnings. Citius Pharmaceuticals posted earnings per share of ($0.04) during the same quarter last year, which would indicate a negative year over year growth rate of 100%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Citius Pharmaceuticals will report full-year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.32) to ($0.19). For the next fiscal year, analysts expect that the firm will report earnings of $0.28 per share, with EPS estimates ranging from $0.15 to $0.41. Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Citius Pharmaceuticals.

Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating) last issued its quarterly earnings data on Thursday, February 10th. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06).

CTXR has been the subject of several research reports. HC Wainwright upped their price objective on shares of Citius Pharmaceuticals from $4.00 to $6.00 and gave the stock a “buy” rating in a report on Tuesday, January 18th. Maxim Group initiated coverage on shares of Citius Pharmaceuticals in a report on Friday, February 11th. They issued a “buy” rating and a $4.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Citius Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, April 8th.

Several institutional investors have recently modified their holdings of CTXR. Morgan Stanley bought a new position in shares of Citius Pharmaceuticals in the 1st quarter worth about $71,000. Royal Bank of Canada bought a new position in shares of Citius Pharmaceuticals in the 2nd quarter worth about $27,000. Bank of America Corp DE purchased a new stake in Citius Pharmaceuticals during the 2nd quarter valued at about $127,000. Citadel Advisors LLC grew its position in Citius Pharmaceuticals by 646.9% during the 2nd quarter. Citadel Advisors LLC now owns 209,208 shares of the company’s stock valued at $728,000 after purchasing an additional 181,199 shares during the last quarter. Finally, Invesco Ltd. purchased a new stake in Citius Pharmaceuticals during the 2nd quarter valued at about $152,000. Institutional investors own 33.53% of the company’s stock.

Shares of NASDAQ CTXR opened at $0.90 on Friday. Citius Pharmaceuticals has a 12 month low of $0.88 and a 12 month high of $4.56. The firm has a market capitalization of $131.08 million, a PE ratio of -4.99 and a beta of 1.64. The firm has a fifty day simple moving average of $1.44 and a two-hundred day simple moving average of $1.57.

Citius Pharmaceuticals Company Profile (Get Rating)

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.

See Also